Daytona Street Capital’s Eledon Pharmaceuticals ELDN Stock Holding History

Daytona Street Capital’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Hold	81,166	–	–	0.23%	92
2026 Q1	$254K	Buy	81,166 +11,000	+16%	+$25.9K	0.2%	104
2025 Q4	$106K	Buy	+70,166	New	+$167K	0.08%	175

Other funds holding ELDN

TCM

Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PAM

Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

PNFS

PW Nova Financial Services Newtown, Pennsylvania $466M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Daytona Street Capital's ELDN Position: Q2 2026 in Review

Daytona Street Capital held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 81,166 shares worth $313K. The position accounts for 0.23% of the portfolio, ranked #92.

Daytona Street Capital first reported a position in ELDN in Q4 2025 and has held it in 3 quarters since. 55 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Daytona Street Capital held 81,166 shares of Eledon Pharmaceuticals worth $313K as of Q2 2026.
Daytona Street Capital left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
Eledon Pharmaceuticals made up 0.23% of Daytona Street Capital's portfolio in Q2 2026, its #92 holding.
Daytona Street Capital first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
55 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Daytona Street Capital's 13F filing for Q2 2026, filed 3 Aug 2026.